Blackstone Invests $337M In Medtronic’s Diabetes R&D

Medtronic plans to rapidly expand its diabetes technology research and development with $337m in new funding from global investment firm Blackstone Life Sciences.

New York, June 27, 2016: Manhattan office location of Blackstone hedge fund.
The Blackstone Group's Manhattan Office

Blackstone Life Sciences will invest $337m over the next several years in Medtronic PLC's diabetes technology research and development efforts, the companies announced on 12 June.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business